Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IK-595 by Ikena Oncology for Solid Tumor: Likelihood of Approval
IK-595 is under clinical development by Ikena Oncology and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
IK-595 by Ikena Oncology for Breast Cancer: Likelihood of Approval
IK-595 is under clinical development by Ikena Oncology and currently in Phase I for Breast Cancer. According to GlobalData, Phase...
IK-595 by Ikena Oncology for Colorectal Cancer: Likelihood of Approval
IK-595 is under clinical development by Ikena Oncology and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
IK-595 by Ikena Oncology for Melanoma: Likelihood of Approval
IK-595 is under clinical development by Ikena Oncology and currently in Phase I for Melanoma. According to GlobalData, Phase I...
IK-595 by Ikena Oncology for Pancreatic Cancer: Likelihood of Approval
IK-595 is under clinical development by Ikena Oncology and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
IK-595 by Ikena Oncology for Glioma: Likelihood of Approval
IK-595 is under clinical development by Ikena Oncology and currently in Phase I for Glioma. According to GlobalData, Phase I...
IK-595 by Ikena Oncology for Non-Small Cell Lung Cancer: Likelihood of Approval
IK-595 is under clinical development by Ikena Oncology and currently in Phase I for Non-Small Cell Lung Cancer. According to...
IK-595 by Ikena Oncology for Thyroid Cancer: Likelihood of Approval
IK-595 is under clinical development by Ikena Oncology and currently in Phase I for Thyroid Cancer. According to GlobalData, Phase...
IK-595 by Ikena Oncology for Nerve Sheath Tumor: Likelihood of Approval
IK-595 is under clinical development by Ikena Oncology and currently in Phase I for Nerve Sheath Tumor. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Ikena Oncology's IK-595?
IK-595 is a small molecule commercialized by Ikena Oncology, with a leading Phase I program in Thyroid Cancer. According to...